Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0062)
Name
Triiodothyronine
Synonyms
liothyronine; triiodothyronine; 3,3',5-Triiodo-L-thyronine; 6893-02-3; Tresitope; Liothyronin; 3,5,3'-triiodothyronine; L-Liothyronine; O-(4-Hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine; T3; 3,5,3'-Triiodo-L-thyronine; triothyrone; Liothyroninum; Lyothyronine; Liotironina; L-T3; 3,3',5-Triiodothyronine; 3,5,3'TRIIODOTHYRONINE; Cyronine; L-3,5,3'-Triiodothyronine; L-3,3',5-TriioDOThyronine; (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid; (S)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoic acid; Triiodo-L-thyronine; L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-; Liothyronine (GMP); Liothyronine (INN); Rathyronine, (s)-; CHEBI:18258; Thyronine, 3,3',5-triiodo-, L-; CHEMBL1544; 4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenylalanine; 06LU7C9H1V; 4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine; 3,5,3'-triiodothyronine, l-; DTXSID8023216; NSC-80203; L-triiodothyronine; Alanine, 3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)-, L-; LIOTHYRONINE [INN]; O-(4-Hydroxy-3-iodophenyl-3,5-diiodo-L-tyrosine; T3 (amino acid); DTXCID403216; T3 liothyronine; Liothyronine [INN:BAN]; Euthroid-1; Euthroid-2; Euthroid-3; Thyrolar-1; Thyrolar-2; Thyrolar-3; (+)-Triiodothyronine; Liotironina [INN-Spanish]; CAS-6893-02-3; Euthroid-0.5; Thyrolar-0.5; T3 (VAN); Thyrolar-0.25; Triiodothyronine, l-; 3,5,3'-Tri-iodo-L-thyronine; Triiodothyronine (T3); SR-05000000455; 5714-08-9; T-3; 3,3',5-Triiodo-D-thyronine; Liothyroninum [INN-Latin]; NSC-46046; 3,3',5-Triiodothyronine, L-; HSDB 3110; 1xzx; (2S)-2-AMINO-3-(4-(4-HYDROXY-3-IODOPHENOXY)-3,5-DIIODOPHENYL)PROPANOIC ACID; Prestwick_135; EINECS 229-999-3; MFCD00002593; NSC 80203; 4-(3-Iodo-4-hydroxyphenoxy)-3,5-diiodophenylalanine; BRN 2710227; Spectrum_001445; L-3-(4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenyl)alanine; Triiodothyronine;3,3',5-Triiodo-L-thyronine;T3; Prestwick0_000853; Prestwick1_000853; Prestwick2_000853; Prestwick3_000853; Spectrum2_001984; Spectrum3_001887; Spectrum4_000326; Spectrum5_001793; LIOTHYRONINE [MI]; Epitope ID:131324; LIOTHYRONINE [HSDB]; SCHEMBL8300; NCIStruc1_000449; LIOTHYRONINE [VANDF]; UNII-06LU7C9H1V; REGID_for_CID_5920; BSPBio_000865; BSPBio_003394; KBioGR_000671; KBioGR_002568; KBioSS_001925; KBioSS_002577; MLS000028458; 3,5,3'-triodo-L-thyronine; LIOTHYRONINE [USP-RS]; LIOTHYRONINE [WHO-DD]; SPBio_002167; SPBio_002786; BPBio1_000953; GTPL2634; HY-A0070AG; L-3,3',5-triiodo-Thyronine; BCBcMAP01_000192; BDBM18860; HY-A0070A; KBio2_001925; KBio2_002568; KBio2_004493; KBio2_005136; KBio2_007061; KBio2_007704; KBio3_002897; KBio3_003046; cMAP_000088; HMS1570L07; HMS2097L07; HMS2235A22; HMS3714L07; LIOTHYRONINE [USP IMPURITY]; TRIIODOTHYRONINE (T3 OR LIOTHYRONINE, ACTIVE) (6-11%); Tox21_110029; Tox21_301943; HB7470; NCGC00013556; s5726; 3,5,3'-triiodo-L-thyronine (T3); (S)-2-Amino-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoicacid; AKOS016003266; 3,3',5-Triiodo-L-thyronine, 95%; AM83597; CCG-220853; CS-4141; DB00279; L-3,3',5-Triiodothyronine, free acid; SMP1_000179; NCGC00013556-01; NCGC00013556-02; NCGC00013556-03; NCGC00013556-04; NCGC00013556-05; NCGC00013556-15; NCGC00096669-01; NCGC00096669-02; NCGC00255336-01; [125I]T3; AC-31935; AS-17446; SMR000058402; SBI-0206718.P001; CS-0622788; T0453; C02465; D08128; EN300-123970; A836290; Q327362; SR-01000003143; SR-01000003143-4; SR-05000000455-2; SR-05000000455-3; 3,3 inverted exclamation mark ,5-Triiodo-L-thyronine; BRD-K89152108-001-03-3; LEVOTHYROXINE SODIUM IMPURITY A [EP IMPURITY]; 3,3',5-Triiodo-L-thyronine, >=95% (HPLC), powder; Z1557400301; D-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]alanine; L-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]-Alanine; Liothyronine, United States Pharmacopeia (USP) Reference Standard; 3,3',5 Triiodothyronine (T3), IRMM(R) certified Reference Material; O-(4-Hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine,labeled with(125i)iodine; Liothyronine, Pharmaceutical Secondary Standard; Certified Reference Material; 57164-27-9

    Click to Show/Hide
Status
Approved
Drug Type
Small molecular drug
Structure
Formula
C15H12I3NO4
IUPAC Name
(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid
Canonical SMILES
C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)O)N)I)I)O
InChI
InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1
InChIKey
AUYYCJSJGJYCDS-LBPRGKRZSA-N
PubChem CID
5920
TTD Drug ID
D0S6JG
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Acute kidney failure ICD-11: GB60
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model CHO-S/H9C2 cells Normal Cricetulus griseus CVCL_A0TS
NRK-49F cells Normal Rattus norvegicus CVCL_2144
HK-2 cells Normal Homo sapiens CVCL_0302
C2C12 cells Normal Mus musculus CVCL_0188
MDA-MB-231 cells Breast adenocarcinoma Homo sapiens CVCL_0062
NRK-52E cells Normal Rattus norvegicus CVCL_0468
LLC-PK1 cells Normal Sus scrofa CVCL_0391
PANC-1 cells Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0480
HT22 cells Normal Mus musculus CVCL_0321
hUPECs (Human urine-derived podocyte-like epithelial cells)
In Vivo Model
C57BL/6N male mice (CLEA Japan), aged 8-9 weeks, were used. AKI was induced by intraperitoneal injection of cisplatin solution (16 or 17 mg/kg as indicated; Nichi-Iko Pharmaceutical). Mice were orally treated with water only, promethazine (20 mg/kg in water), or rifampicin (20 mg/kg in 0.5% methylcellulose) every 12 hours for 4 days starting 30 minutes before the cisplatin injection, or orally treated with promethazine (20 mg/kg) in the following groups: (1) no promethazine, (2) pretreatment 30 minutes before cisplatin injection, (3) treatment from 30 minutes before injection to 24 hours after injection, (4) treatment from 24 to 96 hours after injection, and (5) treatment every 12 hours from 30 minutes before injection to 96 hours after injection.

    Click to Show/Hide
Response regulation Eight drugs and hormones that showed antiferroptotic activity, including omeprazole, indole-3-carbinol, rifampicin, promethazine, carvedilol, propranolol, estradiol, and triiodothyronine. Moreover, in mice, the drugs ameliorated acute kidney injury and liver injury, with suppression of tissue lipid peroxidation and decreased cell death.
References
Ref 1 Drugs Repurposed as Antiferroptosis Agents Suppress Organ Damage, Including AKI, by Functioning as Lipid Peroxyl Radical Scavengers. J Am Soc Nephrol. 2020 Feb;31(2):280-296. doi: 10.1681/ASN.2019060570. Epub 2019 Nov 25.